David A. Siegel Ionis Pharmaceuticals Inc Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,349,211 shares of IONS stock, worth $38.7 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
1,349,211
Previous 1,332,411
1.26%
Holding current value
$38.7 Million
Previous $53.4 Million
11.63%
% of portfolio
0.11%
Previous 0.13%
Shares
30 transactions
Others Institutions Holding IONS
# of Institutions
409Shares Held
131MCall Options Held
829KPut Options Held
789K-
Vanguard Group Inc Valley Forge, PA16.5MShares$472 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.2MShares$406 Million0.31% of portfolio
-
Capital World Investors Los Angeles, CA11.5MShares$329 Million0.06% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$296 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.87MShares$226 Million5.48% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $4.07B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...